Back to top

Image: Bigstock

Constellation Brands' Premiumization and Innovation Aid Growth

Read MoreHide Full Article

Key Takeaways

  • Constellation Brands is leveraging premium labels and innovation to drive long-term growth.
  • STZ continues to invest in its beer, wine and spirits brands to expand market share.
  • STZ is focusing on premiumization and cost savings to strengthen margins and profitability.

Constellation Brands, Inc. (STZ - Free Report) continues to pursue initiatives focused on strengthening its high-end beer portfolio, expanding distribution, driving consumer-led innovation, improving operational efficiency and maintaining financial discipline. The company’s strategy centers on building strong brands with advantaged routes to market while leveraging differentiated brand positioning, price-pack architecture and market prioritization to support growth.

Constellation Brands is strengthening its beer business through investments in its leading imported brands, including Modelo Especial, Corona Extra, Pacifico and Victoria. The company is expanding distribution across off-premise and on-premise channels while investing in additional brewery capacity to support anticipated demand. The company is also pursuing consumer-led innovation through new line extensions, package formats and products designed to address emerging consumer preferences.

Brand differentiation remains another important component of Constellation Brands’ strategy. The company’s beer portfolio is anchored by high-end imported brands, while its wine and spirits business has been repositioned toward an exclusively higher-end portfolio. STZ also continues to expand its wine and spirits brands through U.S. wholesale, international markets and direct-to-consumer channels, including hospitality, to broaden its addressable market.

Constellation Brands is also focused on maintaining market share momentum while improving operational efficiency and cash generation. Hence, Constellation Brands’ investments in its high-end beer portfolio, brewery capacity, distribution network and consumer-led innovation, along with its focus on premium wine and spirits and operational efficiency, provide several avenues to support sales growth, market-share gains and profitability.

STZ’s Price Performance, Valuation & Estimates

Shares of Constellation Brands have lost 19.3% in the past six months compared with the industry’s growth of 11.1%.

Zacks Investment Research
Image Source: Zacks Investment Research

From a valuation standpoint, STZ trades at a forward price-to-earnings ratio of 10.14X compared with the industry’s average of 14.68X.

Zacks Investment Research
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for STZ’s fiscal 2027 and fiscal 2028 earnings per share (EPS) indicates year-over-year growth of 0.2% and 3.6%, respectively. The company’s EPS estimate for fiscal 2027 has been stable, while that of fiscal 2028 has declined in the past seven days.

Zacks Investment Research
Image Source: Zacks Investment Research

Constellation Brands stock currently carries a Zacks Rank #3 (Hold).

Key Consumer Staple Picks

The Chefs' Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East and Canada. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

The Zacks Consensus Estimate for The Chefs' Warehouse’s current financial-year sales and earnings indicates growth of 10.6% and 33.7%, respectively, from the prior-year levels. CHEF delivered a trailing four-quarter earnings surprise of 30.4%, on average.

United Natural Foods (UNFI - Free Report) , a leading distributor of natural, organic and specialty food and non-food products, currently carries a Zacks Rank #2 (Buy).

The Zacks Consensus Estimate for United Natural Foods’ current financial-year sales indicates a rise of 1.3% from the prior-year level. UNFI delivered a trailing four-quarter earnings surprise of 17.9%, on average.

Medifast, Inc. (MED - Free Report) , a leading manufacturer and distributor of clinically-proven healthy living products and programs, currently carries a Zacks Rank of 2. MED missed the average earnings surprise by a sharp margin in the trailing four quarters. 

The Zacks Consensus Estimate for Medifast’s current financial-year sales indicates a decline of 27.3% from the year-ago number. 

Published in